论文部分内容阅读
目的探讨比索洛尔对高血压病并发慢性心力衰竭(CHF)患者脑钠尿肽(BNP)前体(Pro-BNP)的影响。方法选取我院收治的高血压病并发CHF的患者102例,随机分为试药组和对照组各51例。对照组按照高血压病并发CHF的常规治疗方案进行干预,试药组在对照组治疗方案的基础上,加用比索洛尔口服治疗。治疗3个月后对比两组患者的心功能改善情况,同时对比两组患者治疗前后的心率、血压、左室射血分数(LVEF)以及pro-BNP的变化情况。结果试药组的显效率为49%,总有效率为96%,均显著高于对照组(分别为29%,76%,均P<0.05);两组患者治疗后的心率、收缩压和舒张压均显著低于治疗前,而LVEF显著高于治疗前(均P<0.05);试药组治疗后的LVEF为(44±4)%,显著高于对照组〔(35±4)%,P<0.05〕;试药组治疗后的Pro-BNP水平为(733±58)ng/L,对照组治疗后的Pro-BNP水平为(802±63)ng/L,两组患者治疗后的Pro-BNP水显著低于治疗前(均P<0.05);试药组治疗后的Pro-BNP水平显著低于对照组(P<0.05)。结论比索洛尔可有效降低高血压病并发CHF患者的Pro-BNP水平,提高临床疗效。
Objective To investigate the effect of bisoprolol on BNP in patients with hypertension and chronic heart failure (CHF). Methods A total of 102 patients with hypertension complicated with CHF admitted in our hospital were randomly divided into two groups (n = 51) and control group (n = 51). The control group was treated according to the routine treatment of hypertension complicated with CHF. The test group was treated with oral bisoprolol on the basis of the control group. Three months later, the improvement of cardiac function was compared between the two groups. The changes of heart rate, blood pressure, left ventricular ejection fraction (LVEF) and pro-BNP before and after treatment were also compared. Results The effective rate was 49% and the total effective rate was 96% in the test group, which were significantly higher than those in the control group (29% and 76%, respectively, P <0.05). After treatment, heart rate, systolic pressure and (P <0.05). The LVEF of the test group was (44 ± 4)%, which was significantly higher than that of the control group (35 ± 4)%, and the LVEF was significantly higher than that before treatment , P <0.05]. Pro-BNP level in the test group was (733 ± 58) ng / L after treatment, and that in the control group was (802 ± 63) ng / L after treatment (P <0.05). Pro-BNP level in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion Bisoprolol can effectively reduce the level of Pro-BNP in hypertensive patients complicated with CHF and improve the clinical efficacy.